ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310GlobeNewsWire • 04/10/23
Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023GlobeNewsWire • 03/29/23
ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual MeetingGlobeNewsWire • 03/13/23
ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023GlobeNewsWire • 03/13/23
ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent HighlightsGlobeNewsWire • 03/08/23
Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewsWire • 03/08/23
ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent HighlightsGlobeNewsWire • 11/14/22
ValenzaBio Announces Positive Preliminary Data from Phase 1b/2a Trial of VB119, an Anti-CD19 Monoclonal Antibody for the Treatment of Primary Membranous NephropathyBusiness Wire • 11/03/22
ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive OfficerGlobeNewsWire • 09/13/22